The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
There is a big need for therapeutic advancement in the rare disease community – however, public markets are stifling innovation and development for advanced medicines. This webinar, on Thursday, September 15th, will examine the current markets, their effect on the innovation in rare disease drug development, and what we can do to help.
Precision will be at this year’s CAR-TCR summit on September 19-22, 2022, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for CAR and TCR therapies.
As a wave of up-and-coming cell and gene therapies eye the path to approval soon, a combination of uncertainties threatens the waters ahead. A lack of talent, shortage of manufacturing, standardization, and shifting infrastructure are just the beginning of a range of potential issues.
Join Endpoints News and Precision ADVANCE for Cell & Gene Day, a free virtual event on August 24, from 12:00-4:00 PM ET where we convene three distinguished panels of experts to find out where the field stands today and explore funding, development and launch strategies to smooth out the ride to commercialization. You will hear from successful innovators from each facet of the CGTx landscape, including executives from Blackstone, Flagship Pioneering, Monograph Capital, Alliance for Regenerative Medicine, Satellite Bio, Cellevolve Bio, and more.
As payers began to deal with increased costs in 2021 due to deferred care during the COVID-19 pandemic, they still continued to grapple with the prospect of the impact of future gene therapies’ cost, according to industry experts. Precision’s Phil Cyr (SVP) and Erin Lopata (VP, Access Experience Team) weigh in on new ways to pay for the potential flood of gene therapies for rare diseases brewing in the pipeline.
If a genetic therapy was created to cure sickle cell disease, how might this affect the productivity and earnings of an individual with the disease? How might this change also affect wider economic disparities? PRECISIONheor’s Marlon Graf (Senior Research Economist), Rifat Tuly (Research Scientist), and Jeff Sullivan (Senior Director) recently constructed a model to answer these impactful questions.
The advanced therapies sector is growing exponentially. The Alliance for Regenerative Medicine (ARM) reports that the sector raised $23.1 billion in 2021 – a 16% year-over-year increase. That figure includes $1.9 billion in private financing and $9.8 billion in venture funding.
Precision experts Travis Harrison: VP, Bioassay Solutions (Precision for Medicine), Reed Lyon: Director, Business Development (Precision for Medicine), and Pallavi Chhabra: Director, Business Development (Precision for Medicine) will be exhibiting at ASGCT Annual from May 16-19 in Washington, D.C. Travis Harrison will also be giving a presentation on, “Key Considerations for Design and Implementation of Nab Bioassays in Gene Therapy Development” on May 17 at 1PM EST.
The commercialization of cell and gene therapies raises several complex conversations and questions for employers and payers. Without proper solutions and partnerships, employers and health insurers will be held responsible for extreme medical costs associated with gene therapy.
In recent years, the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are transforming the way diseases are treated but are also aiming to cure entirely new patient populations. 2021 saw record-breaking investments across the board, with a 16% increase from the previous year, totaling $23.1billion raised. However, the question remains as to whether this will continue in 2022. As public markets adjust and the economy recovers in early 2022, investments in the cell and gene therapy space may plateau.
Advances in stem cell technology, combined with the increasing prevalence of chronic diseases, are driving rapid growth in the regenerative medicine category, which is predicted to generate $39.33 billion in revenue by 2023.